



EXPRESS MAIL LABEL NO.: EV333997295US DATE: 05-25-2004

**RESPONSE TO  
OFFICE ACTION**

Address to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Attorney Docket No.	RIGL-008CIP
Confirmation No.	6653
First Named Inventor	LUO, YING
Application Number	09/715,725
Filing Date	November 16, 2000
Group Art Unit	1642
Examiner Name	UNGAR, SUSAN NMN
Title:	<i>"NOVEL IAPS ASSOCIATED CELL CYCLE PROTEINS, COMPOSITIONS AND METHODS OF USE"</i>

Sir:

This communication is responsive to the Office Action dated February 6, 2004 for which a three month period for response was given making this response due on or before May 6, 2004. A Notice of Appeal was filed on May 6, 2004. Accordingly, this response is timely filed.

11/24/04  
entered

**AMENDMENTS TO THE CLAIMS**

Please amend claims 27 and 30, as shown below. A complete listing of the claims, including their current status, is set forth below.

1-25. (Cancelled)

26. (Previously presented) A recombinant ING2 protein encoded by the contiguous polynucleotide sequence of nucleotides 120-845 of the nucleic acid set forth in SEQ ID NO:7.

27. (Currently amended) A recombinant ING2 protein, comprising an amino acid sequence having at least 95% sequence identity to the contiguous sequence set forth in SEQ ID NO:8, wherein said recombinant ING2 protein increases transcription from a p53 binding site controlled promoter when introduced into a mammalian cell~~binds to an inhibitor of apoptosis protein (IAP).~~

28. (Cancelled)

29. (Previously presented) A recombinant ING2 protein, consisting essentially of the contiguous amino acid sequence set forth SEQ ID NO:8.

30. (Currently amended) The recombinant ING2 protein of claim 29, wherein said ING2 protein increases transcription from a p53 binding site controlled promoter when introduced into a mammalian cell~~will bind to an inhibitor of apoptosis protein (IAP).~~

31. (Cancelled)

32. (Previously presented) The isolated protein of claim 27, wherein said isolated protein has the contiguous amino acid sequence set forth in SEQ ID NO:8.

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number RIGL-008CIP.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: May 26, 2004

By: James S. Keddie  
James S. Keddie, Ph.D.  
Registration No. 48,920

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231

F:\DOCUMENT\RIGL (Rigel)\008CIP\Response to 02-06-04 final office action.doc